Abstract:The coronavirus disease 2019 (COVID-19) pandemic has affected health and economy worldwide on an unprecedented scale. Patients have diverse clinical outcomes, but those with preexisting cardiovascular disease, hypertension, and related conditions incur disproportionately worse outcome. The high infectivity of severe acute respiratory syndrome coronavirus 2 is in part related to new mutations in the receptor binding domain, and acquisition of a furin cleavage site in the S-spike protein. The continued viral shedding in the asymptomatic and presymptomatic individuals enhances its community transmission. The virus uses the angiotensin converting enzyme 2 receptor for internalization, aided by transmembrane protease serine 2 protease. The tissue localization of the receptors correlates with COVID-19 presenting symptoms and organ dysfunction. Virus-induced angiotensin converting enzyme 2 downregulation may attenuate its function, diminish its anti-inflammatory role, and heighten angiotensin II effects in the predisposed patients. Lymphopenia occurs early and is prognostic, potentially associated with reduction of the CD4+ and some CD8+ T cells. This leads to imbalance of the innate/acquired immune response, delayed viral clearance, and hyperstimulated macrophages and neutrophils. Appropriate type I interferon pathway activation is critical for virus attenuation and balanced immune response. Persistent immune activation in predisposed patients, such as elderly adults and those with cardiovascular risk, can lead to hemophagocytosis-like syndrome, with uncontrolled amplification of cytokine production, leading to multiorgan failure and death. In addition to the airways and lungs, the cardiovascular system is often involved in COVID-19 early, reflected in the release of highly sensitive troponin and natriuretic peptides, which are all extremely prognostic, in particular, in those showing continued rise, along with cytokines such as interleukin-6. Inflammation in the vascular system can result in diffuse microangiopathy with thrombosis. Inflammation in the myocardium can result in myocarditis, heart failure, cardiac arrhythmias, acute coronary syndrome, rapid deterioration, and sudden death. Aggressive support based on early prognostic indicators with expectant management can potentially improve recovery. Appropriate treatment for heart failure, arrhythmias, acute coronary syndrome, and thrombosis remain important. Specific evidence-based treatment strategies for COVID-19 will emerge with ongoing global collaboration on multiple approaches being evaluated. To protect the wider population, antibody testing and effective vaccine will be needed to make COVID-19 history.

Influence of COVID-19 on Cerebrovascular Disease and its Possible Mechanism

Effects of COVID-19 on Arrhythmia

Potential mechanisms of cerebrovascular diseases in COVID-19 patients

2023 Chinese Expert Consensus on the Impact of COVID-19 on the Management of Cardiovascular Diseases

COVID-19 Associated Ischemic Stroke and Hemorrhagic Stroke: Incidence, Potential Pathological Mechanism, and Management

Coronavirus disease 2019 and acute cerebrovascular events: a comprehensive overview

COVID-19 and the cardiovascular system: a study of pathophysiology and interpopulation variability

The Association of Cerebrovascular Disease with Adverse Outcomes in COVID-19 Patients: A Meta-Analysis Based on Adjusted Effect Estimates

COVID-19 and cerebrovascular diseases: a comprehensive overview

Cardiovascular Disease Potentially Contributes to the Progression and Poor Prognosis of COVID-19

The Science Underlying COVID-19: Implications for the Cardiovascular System

Impact of the COVID-19 Pandemic Lockdown on Hospitalizations for Cerebrovascular Disease and Related In-Hospital Mortality in China: A Nationwide Observational Study

Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study

Crosstalk Between Coronavirus Disease 2019 and Cardiovascular Disease and Its Treatment

COVID-19 and Cerebrovascular Disease

Clinical course and outcomes of COVID-19 patients with a history of cerebrovascular disease: a retrospective study in Wuhan

Clinical Course and Mortality of Stroke Patients With Coronavirus Disease 2019 in Wuhan, China

Cardiovascular disease during the COVID-19 pandemic: Think ahead, protect hearts, reduce mortality

Cardiovascular considerations for patients with COVID-19 and candidate drugs against SARS-CoV-2

Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment

COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options